SCHEMBL2196175

SCHEMBL2196175

Cn1c(-c2ccccc2)c(-c2ccccc2)n(C)c1=[Pt].IN(I)C1CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
MAPK1 P28482 1/20 0.35
SLC6A2 P23975 4/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33
ALDH1A1 P00352 6/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
KDM4E B2RXH2 1/20 0.33
HTR2A P28223 2/20 0.32
HTR2C P28335 1/20 0.32
LMNA P02545 2/20 0.31
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31
DRD3 P35462 1/20 0.31
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194997 0.95 ALDH1A1 (0.34) TSHRSMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL2195495 0.94 ALDH1A1 (0.36) TSHRSMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL2192492 0.92 ALDH1A1 (0.38) TSHRSMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL2194479 0.92 ALDH1A1 (0.38) TSHRSMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL2193962 0.81 DDB1 (0.34) LMNA
SCHEMBL2192956 0.79 DRD2 (0.35) TSHRPOLBMAPK1ALDH1A1HPGD
SCHEMBL2194497 0.79 DRD3 (0.34) SLC6A2SLC6A4SLC6A3DRD2DRD4
SCHEMBL2194623 0.77 ALDH1A1 (0.38) TSHRSMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL2197224 0.77 ALDH1A1 (0.38) TSHRSMN1; SMN2POLBMAPK1ALDH1A1
SCHEMBL2197553 0.77 DDB1 (0.33) ALDH1A1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 TSHR 193/4885SMN1; SMN2 4069/4885POLB 760/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 TSHR 193/4885SMN1; SMN2 4069/4885POLB 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.